Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Everolimus in Advanced Renal Cell Carcinoma
NCT01668784Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2012
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of nivolumab in clear cell renal cell carcinoma (ccRCC), sponsored by Bristol Myers Squibb. Started Oct 2012; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01668784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01668784.